A RARE CASE OF HUNTER SYNDROME – CASE REPORT

• Main Authors: Lorena Elena Melit, Oana Marginean, Carmen Duicu, Cristina Campean, Maria Oana Marginean
• Format: Article
• Language: English
• Published: Amaltea Medical Publishing House 2015-03-01
• Series: Romanian Journal of Pediatrics
• Subjects: hunter syndrome; child
• Online Access: https://revistemedicale.amaltea.ro/Romanian_Journal_of_PEDIATRICS/Revista_Romana_de_PEDIATRIE-2015-Nr.1/EN/RJP_2015_1_EN_Art-08.pdf
• ISSN: 1454-0398; 2069-6175

Mucopolysaccharidoses (MPSs) are a group of rare genetic disorders within the larger family of lysosomal diseases. MPSs disorders are caused by a defi ciency in the activity of a specifi c lysosomal enzyme required for the degradation of glycosaminoglycans (GAGs). MPS type II, also called Hunter syndrome consists in a defi - ciency of an enzyme, iduronate-2-sulphatase. We present a rare case of Hunter syndrome with atypical presentation. It is a case about a boy of 2.7 year old who presented to the Paediatric Clinic with symptoms of a respiratory tract infection and a history of frequent ear infections and respiratory tract infections. His clinical examination showed the following abnormalities: high stature, moderately overweight, facial dismorphism (coarse facial features, prominent forehead, a depressed nasal bridge), small stubby fi ngers with fl exion of distal interphalangeal joints, joint stiffness, protruding abdomen with umbilical hernia, hepatomegaly and splenomegaly, and also mild mental retardation. The clinical aspect was suggestive for MPS type I, II or VII. Dosage of enzymes with role in mucopolysaccharide lysosomal metabolism revealed low levels of iduronate-2-sulphatase, changes that bent for MPS type II. Enzymatic diagnosis was confi rmed by molecular DNA analysis that showed a hemizygote mutation of iduronate2-sulphatase gene in intron 3 (c.419-2A > G). Enzyme replacement therapy with recombinant human iduronate2-sulfatase (Elaprase®) was started. The evolution of the case after almost two years of treatment with Elaprase is favorably, without loss of neurological acquisitions.